As we aim to improve the identification and therapeutic management of those at high
cardiovascular risk, certain less traditional risk markers are being more closely investigated.
With growing evidence to support its relation to risk, microalbuminuria is becoming more
widely recognised as an important marker in this assessment. Dr Paul Newman examines the
evidence and seeks to rationalise a valid therapeutic strategy for high risk patients.